首页> 外文学位 >The development of general pharmacokinetic model for combined quercetin and metabolites: A low bioavailable compound with high bioavailable metabolites.
【24h】

The development of general pharmacokinetic model for combined quercetin and metabolites: A low bioavailable compound with high bioavailable metabolites.

机译:槲皮素和代谢物组合的一般药代动力学模型的开发:具有低生物利用度的化合物和具有高生物利用度的代谢物。

获取原文
获取原文并翻译 | 示例

摘要

Quercetin (3,5,7,3,4-pentahydroxyflavanone) is a putative active compound which is widely distributed in many dietary and medicinal plants including vegetables, onion, apple, tea, ginkgo biloba, allium cepa, solanum lycopersicum, and others.; To verify and understand the poor absorption or bioavailability of unchanged quercetin, the present study proposes to clarify various factors associated with unchanged quercetin absorption in vivo: (1) first pass in the gut, liver, and lung; (2) re-absorption; and (3) elimination in rats. Based on these results, a mathematical model to describe the pharmacokinetics (i.e. concentration time curve of unchanged quercetin following oral administration) will be constructed.; Quercetin was dissolved in hydroxypropyl-beta-cyclodextrin solution (about 4mg/ml) and then administered to rats by gastric gavage or intra-vascularly at a dose of 10mg/kg. The plasma concentrations of unchanged quercetin and total quercetin (unchanged quercetin + glucuronides/sulfates of quercetin) in rats were determined by HPLC. The bioavailabilities of unchanged quercetin and total quercetin were obtained by comparing the AUC in systemic circulation after oral and iv administration. Excretions from urine and feces were determined after iv administration. In addition, the elimination from bile was investigated in bile duct cannulated rats following iv administration of quercetin. The rate and extent of absorption was evaluated by comparing the AUC in portal vein plasma and in systemic circulation after oral administration. The “gut effect” was evaluated by comparing the differences in AUC after oral, intraportal, and iv administration.; The results showed that only 3.5% of unchanged quercetin was available in the systemic circulation although the total absorbed quercetin (unchanged quercetin plus conjugated metabolites absorbed) was as high as 59.1%. Following oral administration, 93.3% of oral quercetin was practically metabolized in the gut lumen and gut wall. Only about 3.1% of oral dose was actually metabolized in the liver. Pulmonary first-pass effect did not play an important role in the glucuronidation/sulfation of unchanged quercetin. Conjugated quercetins were mostly excreted into the bile and then into the duodenum, only trace amount of the conjugates of quercetin were reabsorbed. Unchanged quercetin was not found in bile. Less than 1% of dose was excreted in the urine and feces as unchanged quercetin. (Abstract shortened by UMI.)
机译:槲皮素(3,5,7,3 ',4 '-五羟基黄酮)是一种推定的活性化合物,广泛分布于许多饮食和药用植物中,包括蔬菜,洋葱,苹果,茶,银杏叶,葱属cepa,番茄茄子等。为了验证和了解槲皮素不变的吸收或生物利用度差,本研究建议阐明与槲皮素不变的体内吸收有关的各种因素:(1)在肠道,肝脏和肺中的首次通过; (2)重新吸收; (3)消除大鼠。基于这些结果,将建立描述药代动力学的数学模型(即口服后槲皮素未改变的浓度时间曲线)。将槲皮素溶解在羟丙基-β-环糊精溶液(约4mg / ml)中,然后通过胃管灌胃或血管内以10mg / kg的剂量施用于大鼠。通过HPLC测定大鼠中未定槲皮素和总槲皮素(不变的槲皮素+葡萄糖醛酸苷/槲皮素的硫酸盐)的血浆浓度。通过比较口服和 iv 给药后体循环中的AUC,获得未改变的槲皮素和总槲皮素的生物利用度。在 iv 给药后确定尿液和粪便中的排泄物。此外,对槲皮素 iv 给药后的胆管插管大鼠进行了胆汁清除研究。通过比较口服给药后门静脉血浆和全身循环中的AUC来评估吸收的速率和程度。通过比较口服,门内和 iv 给药后AUC的差异来评估“肠道效应”。结果显示,尽管总吸收的槲皮素(不变的槲皮素加吸收的共轭代谢产物)高达59.1%,但在全身循环中只有3.5%的槲皮素可用。口服后,实际上93.3%的口服槲皮素在肠腔和肠壁中被代谢。实际上只有约3.1%的口服剂量在肝脏中代谢。肺首过效应在未改变的槲皮素的葡萄糖醛酸化/硫酸化中没有发挥重要作用。结合的槲皮素主要排入胆汁,然后排入十二指肠,仅微量吸收槲皮素的结合物。在胆汁中未发现槲皮素不变。不到1%的剂量以不变的槲皮素排泄到尿液和粪便中。 (摘要由UMI缩短。)

著录项

  • 作者

    Chen, Xiao.;

  • 作者单位

    Chinese University of Hong Kong (People's Republic of China).;

  • 授予单位 Chinese University of Hong Kong (People's Republic of China).;
  • 学科 Health Sciences Pharmacy.; Health Sciences Pharmacology.
  • 学位 Ph.D.
  • 年度 2003
  • 页码 195 p.
  • 总页数 195
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药剂学;药理学;
  • 关键词

  • 入库时间 2022-08-17 11:45:51

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号